On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.